Data / Drug companies / HF Acquisition Co LLC, DBA HealthFirst
HF Acquisition Co LLC, DBA HealthFirst: 357 products in the FDA NDC directory, labeler code 51662
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
HF Acquisition Co LLC, DBA HealthFirst (labeler code 51662) lists 357 products in the FDA National Drug Code Directory, covering 164 finished drugs by generic name. By type: 342 prescription drugs, 15 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on July 10, 2026.
The request: Watch HF Acquisition Co LLC, DBA HealthFirst (FDA labeler code 51662): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 51662
- Products in commercial distribution
- 357
- Packages
- 473
- Finished drugs by generic name
- 164
- Prescription products
- 342
- Over the counter products
- 15
- Started marketing in the last 12 months
- 4
- Earliest marketing start
- July 15, 1975
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 220 | 61.6% |
| New drug applications (NDA) | 110 | 30.8% |
| Other unapproved drugs | 13 | 3.6% |
| Over the counter monograph drugs | 11 | 3.1% |
| Authorized generics (NDA) | 2 | 0.6% |
| Biologics (BLA) | 1 | 0.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 342 | 95.8% |
| Over the counter drugs | 15 | 4.2% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 210 | 58.8% |
| Injection | 80 | 22.4% |
| Injection, powder, for solution | 10 | 2.8% |
| Spray | 8 | 2.2% |
| Tablet, film coated | 6 | 1.7% |
| Injection, solution, concentrate | 6 | 1.7% |
| Injection, emulsion | 6 | 1.7% |
| Injection, powder, lyophilized, for solution | 5 | 1.4% |
| Jelly | 4 | 1.1% |
| Tablet | 4 | 1.1% |
| Solution | 3 | 0.8% |
| Tablet, orally disintegrating | 2 | 0.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Flumazenil | 51662-1699 | Injection, solution | Generic drugs (ANDA) | July 10, 2026 |
| Epinephrine | 51662-1708 | Injection | Generic drugs (ANDA) | June 8, 2026 |
| Dobutamine in dextrose | 51662-1705 | Injection, solution | New drug applications (NDA) | March 16, 2026 |
| Dobutamine in dextrose | 51662-1697 | Injection, solution | New drug applications (NDA) | March 16, 2026 |
| Dopamine hydrochloride in dextrose | 51662-1681 | Injection, solution | New drug applications (NDA) | November 5, 2025 |
| Furosemide | 51662-1720 | Injection, solution | Generic drugs (ANDA) | December 13, 2024 |
| Furosemide | 51662-1719 | Injection, solution | Generic drugs (ANDA) | December 13, 2024 |
| Nitroglycerin | 51662-1672 | Spray | New drug applications (NDA) | December 2, 2024 |
| Penicillin g potassium | 51662-1709 | Injection, powder, for solution | Generic drugs (ANDA) | December 1, 2024 |
| Diltiazem Hydrochloride | 51662-1712 | Injection, solution | Generic drugs (ANDA) | June 1, 2024 |
| Chloraprep | 51662-1675 | Solution | New drug applications (NDA) | May 13, 2024 |
| Vasopressin | 51662-1694 | Injection | Generic drugs (ANDA) | May 9, 2024 |
| MEDIQUE APAP acetaminophen | 51662-1273 | Tablet, coated | Over the counter monograph drugs | March 27, 2024 |
| Penicillin g potassium | 51662-1689 | Injection, powder, for solution | Generic drugs (ANDA) | March 1, 2024 |
| MEDIQUE APAP EXTRA STRENGTH acetaminophen tablet, film coated | 51662-1274 | Tablet, film coated | Over the counter monograph drugs | January 2, 2024 |
| THIAMINE HYDROCHLORIDE injection, solution | 51662-1635 | Injection, solution | Generic drugs (ANDA) | September 26, 2023 |
| ETOMIDATE injection, solution | 51662-1634 | Injection, solution | Generic drugs (ANDA) | September 25, 2023 |
| Narcan Naloxone HCL | 51662-1642 | Spray | New drug applications (NDA) | August 28, 2023 |
| Naloxone hydrochloride | 51662-1659 | Spray | Generic drugs (ANDA) | July 30, 2023 |
| Rocuronium bromide | 51662-1641 | Injection, solution | Generic drugs (ANDA) | July 17, 2023 |
| Rocuronium bromide | 51662-1640 | Injection, solution | Generic drugs (ANDA) | July 17, 2023 |
| Tranexamic acid | 51662-1714 | Injection, solution | Generic drugs (ANDA) | July 15, 2023 |
| Atropine sulfate | 51662-1627 | Injection, solution | Generic drugs (ANDA) | July 14, 2023 |
| Atropine sulfate | 51662-1626 | Injection, solution | Generic drugs (ANDA) | July 13, 2023 |
| Adenosine | 51662-1632 | Injection, solution | Generic drugs (ANDA) | June 23, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.